CJC-1295 No DAC / Hexarelin

The blend is studied as a pairing of two molecules that reach pituitary somatotrophs through separate receptors. CJC-1295 (No DAC) / Modified GRF 1-29 engages the GHRH receptor, a class B G-protein-coupled receptor that signals through Gs and cyclic AMP; Hexarelin engages the ghrelin / GHS-R1a receptor, a class A GPCR that signals through Gq, phospholipase C, and intracellular calcium. Neuroendocrine research has long examined how these two second-messenger systems converge on the same secretory machinery, and that convergence is the mechanistic rationale researchers cite for studying a GHRH analog and a growth-hormone secretagogue together. The structural basis of the GHRH-receptor arm was characterized by cryo-EM (Nature Communications, 2020), which resolved the human receptor bound to its endogenous ligand and the stimulatory Gs protein and placed it within the shared activation architecture of class B GPCRs such as the GLP-1, PTH1, and calcitonin receptors.

Modified GRF 1-29 is a 29-residue, C-terminally amidated analog of native human GRF(1-29) carrying four substitutions relative to the parent peptide — a D-alanine at position 2 plus changes at positions 8, 15, and 27 — that are studied for how they alter the molecule's susceptibility to enzymatic cleavage and chemical degradation. Jetté et al. (2005) reported the identification and in-vitro characterization of long-acting GRF(1-29) bioconjugates, examining growth-hormone secretion in cultured rat anterior-pituitary cells and pharmacokinetics in rats. An important distinction runs through this literature: the "DAC" (Drug Affinity Complex) version carries a maleimide group that binds covalently to circulating albumin, making it long-circulating, whereas the "No DAC" form studied here lacks that group and is correspondingly short-acting, engaging the receptor in a pulsatile rather than sustained manner. The most-cited human pharmacokinetic work (Teichman et al., 2006) and the GHRH-knockout mouse study (Alba et al., 2006) used the DAC version, so their pharmacokinetics should not be attributed to the No DAC component, which shares the tetrasubstituted backbone but not the albumin-binding behavior. Ionescu and Frohman (2006) examined whether growth-hormone pulsatility persists during continuous stimulation of the GHRH receptor.

Hexarelin is a synthetic hexapeptide agonist of the GHS-R1a (ghrelin) receptor, structurally a methyl-tryptophan-modified analog within the growth-hormone-releasing-peptide class. Its molecular profile and receptor pharmacology have been examined across several model systems. Ghigo et al. (1994) compared growth-hormone responses to Hexarelin and to GHRH across several administration routes in healthy volunteers; Imbimbo et al. (1994) conducted an early dose-ranging study of the growth-hormone response in adults; and Bellone et al. (1995) examined its growth-hormone-releasing activity across developmental stages in a pediatric cohort. Arvat et al. (2001) compared the growth-hormone, prolactin, and corticotroph-axis responses to a ghrelin peptide, Hexarelin, and GHRH — work also cited on the question of endocrine selectivity within the secretagogue class.

A distinct strand of Hexarelin research concerns the scavenger receptor CD36 in cardiac tissue, a target separate from the pituitary growth-hormone axis. Bodart et al. (2002) used photoaffinity cross-linking of cardiac membranes to identify CD36 as a cardiac binding protein for the peptide, with the interaction absent in CD36-null preparations. Subsequent work, including Xu et al. (2017), examined Hexarelin in cardiomyocyte ischemia-reperfusion model systems through both the GHS-R1a and CD36 receptors. This literature is studied for how the peptide's cardiac actions relate to — and can be separated from — its actions on growth-hormone secretion.

The rationale for studying a GHRH analog alongside a growth-hormone secretagogue rests on the convergence of the GHRH-receptor (Gs / cAMP) and GHS-R1a (Gq / calcium) pathways on somatotroph secretion. Bowers et al. (1990) provided a foundational human study of GHRH and growth-hormone-releasing-peptide co-administration; Popovic et al. (1995) examined the same combination in subjects with hypothalamo-pituitary disconnection to localize where each agent acts; Arvat et al. (1994) examined how GHRH interacts with the somatotroph response to Hexarelin across age groups; and Bowers et al. (1996) studied chronic co-administration of a secretagogue with GHRH. An important caveat frames all of this: the published co-administration literature pairs GHRH (or GHRH-analog peptides) with various secretagogues individually, and no controlled study examines the specific Modified GRF 1-29 + Hexarelin pairing. Statements about this exact blend are therefore mechanistic extrapolations from the broader GHRH-plus-secretagogue research, not direct evidence about the pair.